Europe

Ark Therapeutics signs a letter of intent with EMD Millipore

Friday, August 17, 2012 11:13 AM

Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing. 

More... »

EMA to publish and enable access to clinical trial data

Friday, August 17, 2012 09:27 AM

The European Medicines Agency (EMA) will proactively publish clinical trial data and enable access to full data sets by interested parties.

More... »

Elan announces spin-off of discovery science with Neotope Biosciences

Monday, August 13, 2012 11:50 AM

The board of directors of Elan, an Irish neuroscience-focused biotech, has approved the spin-off of discovery science with the separation of Neotope Biosciences from Elan.

More... »

Icon to expand hospital-based presence in translational medicine

Wednesday, August 8, 2012 10:26 AM

Icon, a global provider of outsourced development services, has announced plans to further expand its U.K. hospital-based presence on the Manchester Royal Infirmary Campus.

More... »

Aquapharm Biodiscovery discovers novel antibiotic compound

Monday, August 6, 2012 11:01 AM

Aquapharm Biodiscovery, a Scottish marine biotechnology company, has made a discovery in the development of next-generation antibiotics.

More... »

Recordati acquires Farma-Projekt in Poland

Friday, August 3, 2012 10:48 AM

Recordati, a European pharmaceutical group based in Milan, Italy, has agreed to acquire 100% of the share capital of Farma-Projekt, a Polish pharmaceutical company, for $21.5 million.

More... »

Almirall, Quintiles sign long-term commercial U.K. partnership

Monday, July 30, 2012 10:52 AM

Global pharmaceutical company Almirall and Quintiles, a fully integrated biopharmaceutical services company, have reached a long-term strategic partnership agreement to promote Almirall’s respiratory portfolio in the U.K. commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

More... »

EFPIA supports E.C. adoption of clinical trials regulation

Monday, July 23, 2012 01:01 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), a group of 33 European national pharmaceutical industry associations and 35 companies, welcomes the proposal for a new regulation on clinical trials on medicinal products for human use adopted July 23 by the European Commission as a first step towards further cooperation in the clinical trials assessment process across the E.U.

More... »

Novasep invests $3.6M to boost HPAPI manufacturing capabilities

Monday, July 23, 2012 12:27 PM

Novasep, a global supplier of manufacturing solutions to the life sciences industries, has invested $3.6 million to expand its Highly Potent API (HPAPI) manufacturing capabilities at its facility in Le Mans, France. The expansion has been designed to allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies.

More... »

Oracle to support Cancer Research U.K.’s development of targeted cancer therapies

Tuesday, July 17, 2012 12:05 PM

To support its vision of beating cancer in the United Kingdom, Cancer Research U.K., , a not-for-profit cancer research organization, will work with Oracle Health Sciences Translational Research Center as the foundation for a new analytical environment to help the charity combine the genetic and clinical data from its Stratified Medicine Program.

More... »